NeoGenomics Laboratories, Inc. (NEO) stock: analyst price target and their real reliability
Live quote · data updated Aug 28, 2026
NeoGenomics Laboratories, Inc. · Health Care · ref. ETF XLV · 56 calls · price $18.64
What the company does: NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
📈 NeoGenomics Laboratories, Inc. (NEO) stock price
$18.64+158.5% over range
Aug 28, 25low $7.19 · high $18.64Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 4 analysts
📊 JPI status : NeoGenomics Laboratories, Inc. is no longer in our current JPI rankings, but appeared in the past (2022) — its upside may be behind it. See the stocks picked in 2022 →
⚠️ The stock trades above the median target: it has beaten expectations. The “Buy” reflects conviction on the company, but the remaining quantified upside is low/negative.
🎯 NEO price target & analyst consensus — price $18.64
The price target · all analysts combined (4 targets)
Highest target · 1 firm of 4$25+34.1%
Median target · of 4 targets$17.5-6.1%
Lowest target · 1 firm of 4$14-24.9%
Current price$18.64
Where these 4 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
250%
$19 ↔ $25
Below
250%
$14 ↔ $16
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: Benchmark — 57% of its targets hit on this sector (68 calls tested). It aims for $16 (-14 %), call made on July 25, 2026, maturing on July 25, 2027 (34 d ago).
The 1 reliable analyst
$16-14 %
The 3 other firms
$19+1.9 %
How to read it: the 1 reliable firms are not filtered by optimism — 0 aim above the price, 1 below, hence their $16 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 4 ratings (last 6 months)
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 NEO price target all
All 56 calls, one by one, with our verdict on each firm.
→ See all 56 targets, analyst by analyst💡 The best analysts on NEO most reliable
Their real reliability on NEO, firm by firm: who was right, who was wrong.
→ See their reliability on NEOAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about NeoGenomics Laboratories, Inc.? The JPI assistant answers using our backtest data.
🔎 Detailed analyses
🏛️ Which US Congress members hold NeoGenomics Laboratories, Inc. (NEO)?
2 Congress members have disclosed NEO buys. Click a highlighted name to see their track record (do they beat the S&P 500?).
Dwight Evans 1× · 39%Deborah Ross 1×
✅ Historical analyst reliability on NEO
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| First Analysis | 100% | +64.1% | 3 |
| Raymond James ↗ | 83% | +19.5% | 12 |
| Piper Sandler ↗ | 78% | +37.0% | 9 |
| BTIG ↗ | 75% | +27.6% | 8 |
| Benchmark ↗ | 67% | -1.1% | 9 |
| Cowen & Co. | 67% | -7.1% | 3 |
| SVB Leerink | 50% | -1.4% | 8 |
| Stephens & Co. ↗ | 50% | -33.3% | 4 |
| Needham ↗ | 46% | +8.0% | 28 |
| TD Cowen ↗ | 33% | -20.1% | 3 |
See the other 2 firms
| Goldman Sachs ↗ | 25% | -12.6% | 8 |
| Morgan Stanley ↗ | 33% | -30.7% | 3 |
📊 What $1,000 invested in NeoGenomics Laboratories, Inc. would be worth › open the full page
In short — $1,000 invested in NeoGenomics Laboratories, Inc. 10 years ago would be worth $1,808 today, i.e. +6%/yr on average. Best year: 2019 (+132%), worst: 2022 (-73%). Price performance, excluding dividends.
If I'd invested $1,000 in NeoGenomics Laboratories, Inc.
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $863 | -14% |
| 3 years ago | $1,540 | +54% |
| 5 years ago | $264 | -74% |
Return by year (NeoGenomics Laboratories, Inc.)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +21% | $1,210 (+21%) |
| 2025 | -29% | $863 (-14%) |
| 2024 | +2% | $879 (-12%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on NeoGenomics Laboratories, Inc.
Loading news…
📋 All analyst calls on NEO
Filtered on — · ✕ show all
▲ Buy · 🎯$19
Price at call : $15.27 — upside +24%
Today : $18.64 — upside +2%
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
in progress (365j)
matures : Jul 29, 27
matures : Jul 29, 27
▲ Buy · 🎯$16
Price at call : $13.89 — upside +15%
Today : $18.64 — upside -14%
🎯 on NEO : 0% (3 calls matureds) · 📊 on Health : 48.5% · +3.8% (68 calls)
in progress (365j)
matures : Jul 24, 27
matures : Jul 24, 27
▲ Buy · 🎯$11
Price at call : $9.26 — upside +19%
Today : $18.64 — upside -41%
🎯 on NEO : 0% (3 calls matureds) · 📊 on Health : 48.5% · +3.8% (68 calls)
in progress (365j)
matures : Apr 29, 27
matures : Apr 29, 27
▲ Buy · 🎯$14
Price at call : $9.26 — upside +51%
Today : $18.64 — upside -25%
🎯 on NEO : 50% (2 calls matureds) · 📊 on Health : 55.3% · -0.8% (38 calls)
in progress (365j)
matures : Apr 29, 27
matures : Apr 29, 27
Leerink Partners ↗
Apr 29, 26
▲ Outperform · 🎯$25
Price at call : $8.96 — upside +179%
Today : $18.64 — upside +34%
🎯 on NEO : no call matured yet · 📊 on Health : 50% · -5.3% (10 calls)
in progress (365j)
matures : Apr 29, 27
matures : Apr 29, 27
Piper Sandler ↗
Feb 24, 26
▲ Overweight · 🎯$13
Price at call : $9.82 — upside +32%
Today : $18.64 — upside -30%
🎯 on NEO : 75% (4 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
in progress (365j)
matures : Feb 24, 27
matures : Feb 24, 27
▲ Buy · 🎯$15
Price at call : $11.44 — upside +31%
Today : $18.64 — upside -20%
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
in progress (365j)
matures : Feb 17, 27
matures : Feb 17, 27
▲ Buy · 🎯$14
Price at call : $12.93 — upside +8%
Today : $18.64 — upside -25%
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
in progress (365j)
matures : Jan 12, 27
matures : Jan 12, 27
See the other 48 calls, newest to oldest
▲ Buy · 🎯$12
Price at call : $8.08 — upside +49%
Today : $18.64 — upside -36%
🎯 on NEO : 50% (2 calls matureds) · 📊 on Health : 55.3% · -0.8% (38 calls)
in progress (365j)
matures : Sep 12, 26
matures : Sep 12, 26
Stephens & Co. ↗
Sep 2, 25
▲ Overweight · 🎯$11
Price at call : $8.81 — upside +25%
Today : $18.64 — upside -41%
🎯 on NEO : 0% (1 call matured) · 📊 on Health : 46.4% · +3.2% (84 calls)
in progress (365j)
matures : Sep 2, 26
matures : Sep 2, 26
▲ Buy · 🎯$14
Price at call : $8.81 — upside +59%
Today : $18.64 — upside -25%
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
in progress (365j)
matures : Aug 29, 26
matures : Aug 29, 26
Piper Sandler ↗
Aug 4, 25
▲ Overweight · 🎯$11
Price at call : $5.62 — upside +96%
Today : $18.64 — upside -41%
Expected +96% · Actual +180% · Reason (≥ +15%) : ✓ Yes
🎯 on NEO : 75% (4 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
+179.9%
stock +180% · XLV +24%
matured Aug 4, 26
Morgan Stanley ↗
Jul 30, 25
■ Equal-Weight neutral · not a buy · 🎯$8
Price at call : $4.84 — gap to target +65%
Today : $18.64 — gap to target -57%
🎯 on NEO : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Jul 30, 26
matures : Jul 30, 26
William Blair ↗
Jul 29, 25
■ Market Perform neutral · not a buy
🎯 on NEO : no call matured yet · 📊 on Health : 32% · -10.8% (25 calls)
in progress (365j)
matures : Jul 29, 26
matures : Jul 29, 26
▲ Buy · 🎯$8
Price at call : $5.25 — upside +52%
Today : $18.64 — upside -57%
Expected +52% · Actual +191% · Reason (≥ +15%) : ✓ Yes
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
+190.9%
stock +191% · XLV +24%
matured Jul 29, 26
Piper Sandler ↗
May 6, 25
▲ Overweight · 🎯$12
Price at call : $8 — upside +50%
Today : $18.64 — upside -36%
Expected +50% · Actual +13% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 75% (4 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
+13.4%
stock +13% · XLV +7%
matured May 6, 26
Morgan Stanley ↗
May 1, 25
■ Equal-Weight neutral · not a buy · 🎯$10
Price at call : $7.7 — gap to target +30%
Today : $18.64 — gap to target -46%
🎯 on NEO : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : May 1, 26
matures : May 1, 26
Goldman Sachs ↗
Apr 30, 25
▲ Buy · 🎯$10
Price at call : $7.26 — upside +38%
Today : $18.64 — upside -46%
Expected +38% · Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on NEO : 25% (4 calls matureds) · 📊 on Health : 51% · +5.1% (102 calls)
+30.0%
stock +30% · XLV +6%
matured Apr 30, 26
Leerink Partners ↗
Apr 30, 25
■ Market Perform neutral · not a buy · 🎯$9
Price at call : $6.4 — gap to target +41%
Today : $18.64 — gap to target -52%
🎯 on NEO : no call matured yet · 📊 on Health : 50% · -5.3% (10 calls)
in progress (365j)
matures : Apr 30, 26
matures : Apr 30, 26
▲ Buy · 🎯$8.5
Price at call : $6.4 — upside +33%
Today : $18.64 — upside -54%
Expected +33% · Actual +45% · Reason (≥ +15%) : ✓ Yes
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
+44.7%
stock +45% · XLV +4%
matured Apr 29, 26
Goldman Sachs ↗
Apr 17, 25
▲ Buy · 🎯$15
Price at call : $9.58 — upside +57%
Today : $18.64 — upside -20%
Expected +57% · Actual -14% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 25% (4 calls matureds) · 📊 on Health : 51% · +5.1% (102 calls)
-14.1%
stock -14% · XLV +11%
matured Apr 17, 26
Piper Sandler ↗
Feb 26, 25
▲ Overweight · 🎯$18
Price at call : $9.82 — upside +83%
Today : $18.64 — upside -3%
Expected +83% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 75% (4 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
+0.1%
stock +0% · XLV +9%
matured Feb 26, 26
B of A Securities ↗
Feb 19, 25
■ Neutral neutral · not a buy · 🎯$16
Price at call : $12.72 — gap to target +26%
Today : $18.64 — gap to target -14%
🎯 on NEO : no call matured yet · 📊 on Health : 51.3% · +3.0% (152 calls)
in progress (365j)
matures : Feb 19, 26
matures : Feb 19, 26
▲ Buy · 🎯$18
Price at call : $12.72 — upside +42%
Today : $18.64 — upside -3%
Expected +42% · Actual -21% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-21.3%
stock -21% · XLV +7%
matured Feb 19, 26
Goldman Sachs ↗
Jan 28, 25
▲ Buy · 🎯$18
Price at call : $14.57 — upside +24%
Today : $18.64 — upside -3%
Expected +24% · Actual -15% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 25% (4 calls matureds) · 📊 on Health : 51% · +5.1% (102 calls)
-14.9%
stock -15% · XLV +6%
matured Jan 28, 26
■ Hold neutral · not a buy
🎯 on NEO : 0% (3 calls matureds) · 📊 on Health : 48.5% · +3.8% (68 calls)
in progress (365j)
matures : Jan 16, 26
matures : Jan 16, 26
▲ Buy · 🎯$19
Price at call : $13.98 — upside +36%
Today : $18.64 — upside +2%
Expected +36% · Actual -9% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-8.5%
stock -9% · XLV +10%
matured Jan 15, 26
■ Hold neutral · not a buy
🎯 on NEO : 0% (3 calls matureds) · 📊 on Health : 48.5% · +3.8% (68 calls)
in progress (365j)
matures : Jan 13, 26
matures : Jan 13, 26
▲ Buy · 🎯$19
Price at call : $12.63 — upside +50%
Today : $18.64 — upside +2%
Expected +50% · Actual -1% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-1.1%
stock -1% · XLV +11%
matured Jan 10, 26
B of A Securities ↗
Dec 13, 24
■ Neutral neutral · not a buy · 🎯$19
Price at call : $17.97 — gap to target +6%
Today : $18.64 — gap to target +2%
🎯 on NEO : no call matured yet · 📊 on Health : 51.3% · +3.0% (152 calls)
in progress (365j)
matures : Dec 13, 25
matures : Dec 13, 25
▲ Buy · 🎯$22
Price at call : $18.17 — upside +21%
Today : $18.64 — upside +18%
Expected +21% · Actual -35% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 0% (1 call matured) · 📊 on Health : 50% · +9.9% (136 calls)
-35.2%
stock -35% · XLV +8%
matured Dec 10, 25
▲ Buy · 🎯$19
Price at call : $15.46 — upside +23%
Today : $18.64 — upside +2%
Expected +23% · Actual -33% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-32.7%
stock -33% · XLV -1%
matured Nov 6, 25
▲ Buy · 🎯$19
Price at call : $14.96 — upside +27%
Today : $18.64 — upside +2%
Expected +27% · Actual -47% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-47.4%
stock -47% · XLV -12%
matured Sep 25, 25
▲ Buy · 🎯$18
Price at call : $15.8 — upside +14%
Today : $18.64 — upside -3%
Expected +14% · Actual -50% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 0% (3 calls matureds) · 📊 on Health : 48.5% · +3.8% (68 calls)
-50.2%
stock -50% · XLV -11%
matured Sep 24, 25
Stephens & Co. ↗
Jul 30, 24
▲ Overweight · 🎯$19
Price at call : $17.73 — upside +7%
Today : $18.64 — upside +2%
Expected +7% · Actual -73% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 0% (1 call matured) · 📊 on Health : 46.4% · +3.2% (84 calls)
-72.7%
stock -73% · XLV -13%
matured Jul 30, 25
▲ Buy · 🎯$18
Price at call : $17.27 — upside +4%
Today : $18.64 — upside -3%
Expected +4% · Actual -70% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 0% (3 calls matureds) · 📊 on Health : 48.5% · +3.8% (68 calls)
-70.5%
stock -70% · XLV -11%
matured Jul 30, 25
▲ Buy · 🎯$19
Price at call : $17.27 — upside +10%
Today : $18.64 — upside +2%
Expected +10% · Actual -70% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-70.5%
stock -70% · XLV -11%
matured Jul 30, 25
▲ Buy · 🎯$21
Price at call : $15.3 — upside +37%
Today : $18.64 — upside +13%
Expected +37% · Actual -49% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 75% (8 calls matureds) · 📊 on Health : 46.2% · +19.8% (65 calls)
-48.8%
stock -49% · XLV -2%
matured May 2, 25
▲ Buy · 🎯$20
Price at call : $14.72 — upside +36%
Today : $18.64 — upside +7%
Expected +36% · Actual -48% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 50% (2 calls matureds) · 📊 on Health : 55.3% · -0.8% (38 calls)
-47.7%
stock -48% · XLV -1%
matured May 1, 25
▲ Buy · 🎯$18
Price at call : $14.72 — upside +22%
Today : $18.64 — upside -3%
Expected +22% · Actual -48% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 0% (3 calls matureds) · 📊 on Health : 48.5% · +3.8% (68 calls)
-47.7%
stock -48% · XLV -1%
matured May 1, 25
▲ Buy · 🎯$19
Price at call : $13.96 — upside +36%
Today : $18.64 — upside +2%
Expected +36% · Actual -48% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-48.0%
stock -48% · XLV -3%
matured Apr 30, 25
Piper Sandler ↗
Feb 26, 24
▲ Overweight · 🎯$20
Price at call : $16.13 — upside +24%
Today : $18.64 — upside +7%
Expected +24% · Actual -36% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 75% (4 calls matureds) · 📊 on Health : 45.8% · +6.9% (249 calls)
-35.5%
stock -36% · XLV +1%
matured Feb 25, 25
Goldman Sachs ↗
Feb 22, 24
▲ Buy · 🎯$19
Price at call : $16.45 — upside +16%
Today : $18.64 — upside +2%
Expected +16% · Actual -33% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 25% (4 calls matureds) · 📊 on Health : 51% · +5.1% (102 calls)
-32.5%
stock -33% · XLV -1%
matured Feb 21, 25
▲ Buy · 🎯$24
Price at call : $16.48 — upside +46%
Today : $18.64 — upside +29%
Expected +46% · Actual -28% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-28.0%
stock -28% · XLV +1%
matured Feb 20, 25
▲ Outperform · 🎯$19
Price at call : $16.18 — upside +17%
Today : $18.64 — upside +2%
Expected +17% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 50% (2 calls matureds) · 📊 on Health : 55.3% · -0.8% (38 calls)
+4.6%
stock +5% · XLV +1%
matured Dec 28, 24
▲ Buy · 🎯$21
Price at call : $16.18 — upside +30%
Today : $18.64 — upside +13%
Expected +30% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 75% (8 calls matureds) · 📊 on Health : 46.2% · +19.8% (65 calls)
+4.6%
stock +5% · XLV +1%
matured Dec 28, 24
▲ Buy · 🎯$21
Price at call : $16.79 — upside +25%
Today : $18.64 — upside +13%
Expected +25% · Actual +0% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
+0.2%
stock +0% · XLV +2%
matured Dec 27, 24
Morgan Stanley ↗
Nov 8, 23
■ Equal-Weight neutral · not a buy · 🎯$17
Price at call : $15.72 — gap to target +8%
Today : $18.64 — gap to target -9%
🎯 on NEO : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Nov 7, 24
matures : Nov 7, 24
▲ Buy · 🎯$21
Price at call : $16.73 — upside +26%
Today : $18.64 — upside +13%
Expected +26% · Actual -8% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 25% (12 calls matureds) · 📊 on Health : 39% · -2.9% (397 calls)
-7.6%
stock -8% · XLV +15%
matured Nov 6, 24
Morgan Stanley ↗
Oct 24, 23
■ Equal-Weight neutral · not a buy · 🎯$16
Price at call : $14.75 — gap to target +8%
Today : $18.64 — gap to target -14%
🎯 on NEO : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Oct 23, 24
matures : Oct 23, 24
▲ Buy · 🎯$25
Price at call : $18.25 — upside +37%
Today : $18.64 — upside +34%
Expected +37% · Actual -17% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 75% (8 calls matureds) · 📊 on Health : 46.2% · +19.8% (65 calls)
-17.1%
stock -17% · XLV +7%
matured May 8, 24
▲ Buy · 🎯$28
Price at call : $12.49 — upside +124%
Today : $18.64 — upside +50%
Expected +124% · Actual +41% · Reason (≥ +15%) : ✓ Yes
🎯 on NEO : 75% (8 calls matureds) · 📊 on Health : 46.2% · +19.8% (65 calls)
+40.8%
stock +41% · XLV -8%
matured Mar 29, 23
▲ Outperform
Actual +128% · Reason (≥ +15%) : ✓ Yes
🎯 on NEO : 75% (8 calls matureds) · 📊 on Health : 46.2% · +19.8% (65 calls)
+128.0%
stock +128% · XLV +7%
matured Apr 16, 19
▲ Buy
Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on NEO : 75% (8 calls matureds) · 📊 on Health : 46.2% · +19.8% (65 calls)
+3.9%
stock +4% · XLV +19%
matured Oct 27, 17
▲ Buy · 🎯$7
Price at call : $5.43 — upside +29%
Today : $18.64 — upside -62%
Expected +29% · Actual +55% · Reason (≥ +15%) : ✓ Yes
🎯 on NEO : 75% (8 calls matureds) · 📊 on Health : 46.2% · +19.8% (65 calls)
+54.7%
stock +55% · XLV -8%
matured Jun 22, 16
Frequently asked questions
Should I buy NeoGenomics Laboratories, Inc. stock?
This isn't buy advice. For NeoGenomics Laboratories, Inc., the analyst consensus is "Buy", with an average price target of $17.50 (-6% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (3 calls tracked on NeoGenomics Laboratories, Inc.). We show the numbers — you decide.
Is it too late to buy NeoGenomics Laboratories, Inc.? How high can it go?
The most bullish analyst target on NeoGenomics Laboratories, Inc. is $25.00 (+34% above today's price); the average is $17.50. That's the upside they see. Check how reliable those analysts have actually been on NeoGenomics Laboratories, Inc. on our site before trusting it.
Is NeoGenomics Laboratories, Inc. still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 12 analysts have a real record on NeoGenomics Laboratories, Inc., the best hitting 100% over 3 calls. Current consensus: "Buy". Make your call on data, not noise.
What has NeoGenomics Laboratories, Inc.'s past performance been?
Historical returns and a "how much if I had invested" calculator: NEO performance & returns.
BIIB 
VRTX 
UNH 
REGN 
EW 
SRPT 
VEEV 
BSX